知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.018 seconds)

    Aminotriazole compounds
    2.
    发明授权
    Aminotriazole compounds 失效
    氨基三唑化合物

    公开(公告)号：US06596749B2

    公开(公告)日：2003-07-22

    申请号：US09799199

    申请日：2001-03-05

    Applicant: Jean-Luc Fauchere ,  Jean-Claude Ortuno ,  Jacques Duhault ,  Jean Albert Boutin ,  Nigel Levens

    Inventor： Jean-Luc Fauchere ,  Jean-Claude Ortuno ,  Jacques Duhault ,  Jean Albert Boutin ,  Nigel Levens

    IPC: A61K314196

    CPC classification number: C07D401/12 ,  C07D249/14 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  Y02P20/55

    Abstract: Method of treating with compounds of formula (I): wherein: n is 0 or 1, W represents —CO— or S(O)q and q is 0, 1 or 2, G represents a G1, G2, G3 or G4 group as defined in the description, Z represents alkyl, aryl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, A represents a grouping selected from —A2—, —A1—A2—, —A2—A1—, and —A1—A2—A1— wherein A1 is alkylene and A2 represents phenylene, cycloalkylene, naphthylene or heteroarylene each optionally substituted, R represents hydrogen, alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, R1 represents alkyl, aryl, heteroaryl, arylalkyl arylalkenyl, arylalkynyl, heteroarylakenyl, heteroarylalkynyl or heteroarylalkyl each optionally substituted, and medicinal products containing the same are useful as Neuropeptide Y receptor ligands.

    Abstract translation: 用式（I）化合物处理的方法：其中：n为0或1，W为-CO-或S（O）q，q为0,1或2，G为G1，G2，G3或G4基团 Z表示烷基，芳基，杂芳基，芳基烷基，芳基烯基，芳基炔基，杂芳基酰基，杂芳基炔基或杂芳基烷基，各自任选取代，A表示选自-A2-，-A1-A2-，-A2-A1- 和-A1-A2-A1-，其中A1是亚烷基，A2代表亚苯基，亚环烷基，亚萘基或亚杂芳基，各自任选取代，R表示氢，烷基，芳基，杂芳基，芳基烷基芳基烯基，芳基炔基，杂芳基酰基，杂芳基炔基或杂芳基烷基， R 1表示烷基，芳基，杂芳基，芳基烷基芳基烯基，芳基炔基，杂芳基酰基，杂芳基炔基或杂芳基烷基，各自任选被取代，并且含有它们的医药产品可用作神经肽Y受体配体。

    Sulfonamide derivatives having oxadiazole rings
    4.
    发明授权
    Sulfonamide derivatives having oxadiazole rings 失效
    具有恶二唑环的磺酰胺衍生物

    公开(公告)号：US06495578B1

    公开(公告)日：2002-12-17

    申请号：US09959008

    申请日：2001-10-17

    Applicant: Fumihiko Watanabe ,  Yoshinori Tamura ,  Yasuhiko Fujii

    Inventor： Fumihiko Watanabe ,  Yoshinori Tamura ,  Yasuhiko Fujii

    IPC: A61K314196

    CPC classification number: C07D413/04

    Abstract: Sulfonamide derivatives having a matrix metalloprotease inhibiting effect, which are compounds represented by general formula (I), optical isomers of the same, pharmaceutically acceptable salts of both, or solvates of them: wherein R1 and R2 are each independently hydrogen atom, optionally substituted lower alkyl or the like; R3 is optionally substituted aryl, optionally substituted heteroaryl or the like; X is —CH═CH—, —O—, or —S—; Y is NHOH, hydroxy, or lower alkyloxy.

    Abstract translation: 具有基质金属蛋白酶抑制作用的磺酰胺衍生物，其为通式（I）表示的化合物，其光学异构体，它们的药学上可接受的盐或它们的溶剂合物：其中R1和R2各自独立地为氢原子，任选取代的低级 烷基等; R3是任选取代的芳基，任选取代的杂芳基等; X是-CH = CH-，-O-或-S-; Y是NHOH，羟基或低级烷氧基。

    Arylsulfonanilide ureas
    6.
    发明授权
    Arylsulfonanilide ureas 失效

    公开(公告)号：US06583165B2

    公开(公告)日：2003-06-24

    申请号：US09792669

    申请日：2001-02-21

    Applicant: Jonathan B. Houze

    Inventor： Jonathan B. Houze

    IPC: A61K314196

    CPC classification number: C07D231/38 ,  C07C311/21 ,  C07D295/215 ,  C07D307/52

    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.

    11-&bgr;-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
    9.
    发明授权
    11-&bgr;-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia 有权
    用于治疗糖尿病，肥胖和血脂异常的11-β-羟基类固醇脱氢酶1抑制剂

    公开(公告)号：US06730690B2

    公开(公告)日：2004-05-04

    申请号：US10457682

    申请日：2003-06-09

    Applicant: Steven H. Olson ,  James M. Balkovec ,  Yuping Zhu

    Inventor： Steven H. Olson ,  James M. Balkovec ,  Yuping Zhu

    IPC: A61K314196

    CPC classification number: C07D249/08

    Abstract: Compounds having Formula I, including pharmaceutically acceptable salts, hydrates and solvates thereof: are selective inhibitors of the 11&bgr;-HSD1 enzyme. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dylsipidemia, hyperlipidemia, hypertension, Syndrome X, and other symptoms associated with NIDDM.

    Abstract translation: 具有式I的化合物，包括其药学上可接受的盐，水合物和溶剂化物：是11beta-HSD1酶的选择性抑制剂。 这些化合物可用于治疗糖尿病，例如非胰岛素依赖性糖尿病（NIDDM），高血糖症，肥胖症，胰岛素抵抗，甲状腺脂肪血症，高脂血症，高血压，X综合征和与NIDDM相关的其他症状。

    Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
    10.
    发明授权
    Thiophenyl triazol-3-one derivatives as smooth muscle relaxants 失效
    噻吩三唑-3-酮衍生物作为平滑肌松弛剂

    公开(公告)号：US06613786B2

    公开(公告)日：2003-09-02

    申请号：US10266373

    申请日：2002-10-08

    Applicant: Piyasena Hewawasam ,  John E. Starrett ,  Dalton King ,  Li-Quang Sun ,  Nicholas J. Lodge

    Inventor： Piyasena Hewawasam ,  John E. Starrett ,  Dalton King ,  Li-Quang Sun ,  Nicholas J. Lodge

    IPC: A61K314196

    CPC classification number: C07D409/04

    Abstract: The present invention provides novel [1,2,4]triazole-3-one derivatives having the general formula (I) wherein: Q is  and R1, R2, R3, R4, R5 and R6 are as defined herein or a nontoxic pharmaceutically acceptable salt or solvate thereof which are smooth muscle relaxants and useful in treating disorders responsive to relaxation of smooth muscle such as asthma, irritable bowel syndrome, male erectile dysfunction and urinary incontinence.

    Abstract translation: 本发明提供具有通式（I）的新颖的[1,2,4]三唑-3-酮衍生物，其中：Q是且R 1，R 2，R 3，R 4，R 5和R 6如本文所定义或无毒的药学上可接受的 盐或其溶剂化物，其是平滑肌松弛剂，并且可用于治疗对平滑肌松弛有响应的疾病，例如哮喘，肠易激综合征，男性勃起功能障碍和尿失禁。

Patent Agency Ranking